TMCnet News
Cyprus Chooses Implant Sciences' QS-B220 to Meet Upcoming EU ETD RegulationsWILMINGTON, Mass., June 23, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 8 of its QS-B220 desktop explosives trace detectors to two major international airports in Cyprus, Paphos and Larnaca, which will be subject to the upcoming EU ETD regulations. "The adoption of our QS-B220 by large and small EU countries alike speaks volumes. We believe that these smaller countries invest in technology that has the best reputation, or is seen as a 'sure thing'. We are very proud and gratified to be recognized by Cyprus and other countries, big and small, as the leader in trace detection," stated Dr. Bill McGann, Implant Sciences' CEO. "Indeed, this series of sales throughout Europe is a true example of a positive cycle for Implant Sciences. We believe that when a well-known airport selects our technology, it can lead to more positive customer reference sites which, in turn, can lead to additional sales for our company," added Dr. Darryl Jones, Implant Sciences' Vice President of Global Sales and Marketing. "Implant Sciences is proud to supply systems all across the EU to support the first EU ETD deadline in September." About the QS-B220 Desktop Explosives Trace Detector The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to dsktop trace detection users with unsurpassed ease of use. About Implant Sciences Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 60 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the GSN Homeland Security Award for "Best Explosives Detection Solution" two years in a row (2013 and 2014). All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com. Cautionary Note Regarding Forward-Looking Statements This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. Contact: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cyprus-chooses-implant-sciences-qs-b220-to-meet-upcoming-eu-etd-regulations-300103184.html SOURCE Implant Sciences Corporation 
|